Global Co‐Occurrence Patterns of Ischemic Heart Disease and Metabolic Dysfunction–Associated Steatotic Liver Disease: Spatial Clusters, Risk Factors, and Quality‐of‐Care Index

BACKGROUND: Ischemic heart disease and metabolic dysfunction-associated steatotic liver disease represent significant global health challenges, characterized by overlapping pathophysiological mechanisms. A comprehensive understanding of their spatial co-occurrence, common risk factors, and disparities in health care quality is essential for the development of integrated prevention and treatment strategies. METHODS: Using data from the 2021 GBD (Global Burden of Disease) study, encompassing 204 countries and territories, we conducted an analysis of the spatial co-occurrence patterns of ischemic heart disease and metabolic dysfunction-associated steatotic liver disease. To identify principal risk factors, we used machine learning techniques, specifically Shapley Additive Explanations, alongside negative binomial regression models. Furthermore, the Quality-of-Care Index was computed to assess the alignment of health care services with the disease burden. RESULTS: A notable spatial co-occurrence of ischemic heart disease and metabolic dysfunction-associated steatotic liver disease was identified, especially prevalent in regions such as the Middle East, North Africa, and emerging economies. The primary shared risk factors encompassed kidney dysfunction, high body mass index, and ambient particulate matter pollution. Disparities in the Quality-of-Care Index were apparent, with regions including Eastern Europe, South Asia, and certain areas of Africa exhibiting insufficient health care resources in comparison with the burden of disease. CONCLUSIONS: The comorbidity of ischemic heart disease and metabolic dysfunction-associated steatotic liver disease constitutes a significant global health concern. Implementing comprehensive interventions aimed at addressing risk factors has the potential to mitigate the worldwide burden of cardiometabolic diseases.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-04-28
DOI
https://doi.org/10.1161/jaha.125.046981
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global Co‐Occurrence Patterns of Ischemic Heart Disease and Metabolic Dysfunction–Associated Steatotic Liver Disease: Spatial Clusters, Risk Factors, and Quality‐of‐Care Index

W J Liu, Jinhui Sun, Wei-Dong Jiang, Lin Wang et al.
Journal of the American Heart Association
Liver Disease Diagnosis and Treatment
article

Global Co‐Occurrence Patterns of Ischemic Heart Disease and Metabolic Dysfunction–Associated Steatotic Liver Disease: Spatial Clusters, Risk Factors, and Quality‐of‐Care Index

W J Liu, Jinhui Sun, Wei-Dong Jiang, Lin Wang, Shi Qiu, Zi‐jia Li, Wei Wang, Ze‐zhong Wu, Ai‐qiong Qin
article en

Abstract

BACKGROUND: Ischemic heart disease and metabolic dysfunction-associated steatotic liver disease represent significant global health challenges, characterized by overlapping pathophysiological mechanisms. A comprehensive understanding of their spatial co-occurrence, common risk factors, and disparities in health care quality is essential for the development of integrated prevention and treatment strategies. METHODS: Using data from the 2021 GBD (Global Burden of Disease) study, encompassing 204 countries and territories, we conducted an analysis of the spatial co-occurrence patterns of ischemic heart disease and metabolic dysfunction-associated steatotic liver disease. To identify principal risk factors, we used machine learning techniques, specifically Shapley Additive Explanations, alongside negative binomial regression models. Furthermore, the Quality-of-Care Index was computed to assess the alignment of health care services with the disease burden. RESULTS: A notable spatial co-occurrence of ischemic heart disease and metabolic dysfunction-associated steatotic liver disease was identified, especially prevalent in regions such as the Middle East, North Africa, and emerging economies. The primary shared risk factors encompassed kidney dysfunction, high body mass index, and ambient particulate matter pollution. Disparities in the Quality-of-Care Index were apparent, with regions including Eastern Europe, South Asia, and certain areas of Africa exhibiting insufficient health care resources in comparison with the burden of disease. CONCLUSIONS: The comorbidity of ischemic heart disease and metabolic dysfunction-associated steatotic liver disease constitutes a significant global health concern. Implementing comprehensive interventions aimed at addressing risk factors has the potential to mitigate the worldwide burden of cardiometabolic diseases.

Journal of the American Heart AssociationVol. 15(9)
Second Hospital of Shandong University (CN), Jinan Central Hospital (CN), Qilu Hospital of Shandong University (CN), Shandong First Medical University (CN)
Partnerships for the goals
Openalex Percentile: Top 17%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.